José M. Viéitez

José M. Viéitez

Auto-generated profile, based on publicly available information

José M. Viéitez

Hospital Universitario Central de Asturias, Oviedo, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in European Journal of Cancer
Verified
Journal Article
Open access
GAGuillem Argilés
Guillem Argilés
NMNuria Mulet
Nuria Mulet
MAMANUEL VALLADARES AYERBES
MANUEL VALLADARES AYERBES
JVJosé M. Viéitez
José M. Viéitez
CGCristina Grávalos
Cristina Grávalos
DMD. Malka
D. Malka
The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients. Patients with mCRC and progression during or within 3 months following their last standard chemotherapy regimen were randomised to receive the approved dose of regorafenib of 160 mg QD (arm A) or 120 mg QD (arm B) administered as 3 weeks of treatment followed by 1 week off, or 160 mg QD 1 week on/1 week off (arm C). The primary end-point was the percentage of patients with G3/G4 treatment-related adverse events (AEs) in each arm. There were 299 patients randomly assigned to arm A (n = 101), arm B (n = 99), or arm C (n = 99); 297 initiated treatments (arm A n = 100, arm B n = 98, arm C n = 99: population for safety analyses). G3/4 treatment-related AEs occurred in 60%, 55%, and 54% of patients in arms A, B, and C, respectively. The most common G3/4 AEs were hypertension (19, 12, and 20 patients), fatigue (20, 14, and 15 patients), hypokalemia (11, 7, and 10 patients), and hand-foot skin reaction (8, 7, and 3 patients). Median overall survival was 7.4 (IQR 4.0-13.7) months in arm A, 8.6 (IQR 3.8-13.4) in arm B, and 7.1 (IQR 4.4-12.4) in arm C. The alternative regorafenib dosing schedules were feasible and safe in patients with mCRC who had been previously treated with standard therapy. There was a higher numerical improvement on the most clinically relevant AEs in the intermittent dosing arm, particularly during the relevant first two cycles. NCT02835924.

23 October 2018 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
PAP. García Alfonso
P. García Alfonso
MAMANUEL VALLADARES AYERBES
MANUEL VALLADARES AYERBES
JLJ. Muñoz Luengo
J. Muñoz Luengo
PPP. Pimentel
P. Pimentel
JVJ.M. Viéitez
J.M. Viéitez
AVA. Lloansí Vila
A. Lloansí Vila
Background: Tumour-tissue biopsy testing is the standard of care (SOC) to assess RAS mutation in mCRC pts. However, the analysis of circulating cell-free DNA (cfDNA) has the added advantage of being able to evidence genetic tumour heterogeneity. We explored the correlation of the RAS mutational status assessed in plasma samples with first-line (1L) treatment outcomes in SOC RAS wild type (wt) mCRC pts.